News & Updates
Filter by Specialty:

Topical NSAID treatment after selective laser trabeculoplasty of no benefit in glaucoma patients
The use of topical nonsteroidal anti-inflammatory drug (NSAID) does not seem to enhance the efficacy of selective laser trabeculoplasty for patients with glaucoma, as shown in a study.
Topical NSAID treatment after selective laser trabeculoplasty of no benefit in glaucoma patients
14 Apr 2023
Systemic antihypertensive medications exert diverse effects on glaucoma, IOP
The effects of systemic antihypertensive medications on glaucoma and intraocular pressure (IOP) appear to vary widely, according to the results of a systematic review and meta-analysis.
Systemic antihypertensive medications exert diverse effects on glaucoma, IOP
31 Mar 2023
How does gel stent perform vs trabeculectomy in open-angle glaucoma?
In the treatment of patients with open-angle glaucoma (OAG), gel stent is noninferior to trabeculectomy in terms of reducing intraocular pressure (IOP) by at least 20 percent, according to a study. Trabeculectomy helps reduce IOP to a greater extent, whereas gel stent leads to fewer adverse events (AEs).
How does gel stent perform vs trabeculectomy in open-angle glaucoma?
30 Mar 2023
Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial
The novel NOV03 ophthalmic drop consisting of perfluorohexyloctane appears to help reduce both signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD), as shown in the results of the phase III MOJAVE study.
Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial
25 Mar 2023
Bidirectional genetic link exists between myopia, POAG
Myopia and primary open-angle glaucoma (POAG) share a strong bidirectional, genetic, causal relationship, which is primarily driven by intraocular pressure (IOP), suggest the results of a study.
Bidirectional genetic link exists between myopia, POAG
24 Mar 2023
Prophylactic aflibercept reduces vision-threatening complications without gains in visual acuity
Treatment with intravitreal aflibercept in patients with nonproliferative diabetic retinopathy but without centre-involved diabetic macular edema appears to slow disease progression and reduce the risk of developing vision-threatening complications but fall short of improving visual acuity, according to a study.